Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]

Affiliations

¹ Istituto Europeo di Oncologia, Milan, IRCCS; University of Milano, Milan, Italy.
² Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.
³ University of Colorado Hospital, Aurora.
⁴ Sarah Cannon Research Institute/Tennessee Oncology e Nashville, Nashville.
⁵ University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA.
⁶ Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ MD Anderson Cancer Center, Houston, USA.
⁸ The Royal Marsden NHS Foundation Trust, London, UK.
⁹ Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, USA.
¹⁰ Edinburgh Cancer Research Centre, Edinburgh, UK.
¹¹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
¹² British Columbia Cancer e Vancouver Centre, Vancouver, Canada.
¹³ Dana-Farber Cancer Institute, Boston, USA.
¹⁴ German Breast Group, Neu-Isenburg, Germany.
¹⁵ Stanford Cancer Institute, Palo Alto, USA.
¹⁶ Seagen Inc., Bothell, USA.

Free article

Published Erratum

G Curigliano et al. Ann Oncol. 2023 Jul.

Free article

. 2023 Jul;34(7):630.

doi: 10.1016/j.annonc.2022.12.005. Epub 2022 Dec 21.

¹ Istituto Europeo di Oncologia, Milan, IRCCS; University of Milano, Milan, Italy.
² Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Germany.
³ University of Colorado Hospital, Aurora.
⁴ Sarah Cannon Research Institute/Tennessee Oncology e Nashville, Nashville.
⁵ University of California, Los Angeles/Jonsson Comprehensive Cancer Center, Los Angeles, USA.
⁶ Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷ MD Anderson Cancer Center, Houston, USA.
⁸ The Royal Marsden NHS Foundation Trust, London, UK.
⁹ Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, USA.
¹⁰ Edinburgh Cancer Research Centre, Edinburgh, UK.
¹¹ UNC Lineberger Comprehensive Cancer Center, Chapel Hill, USA.
¹² British Columbia Cancer e Vancouver Centre, Vancouver, Canada.
¹³ Dana-Farber Cancer Institute, Boston, USA.
¹⁴ German Breast Group, Neu-Isenburg, Germany.
¹⁵ Stanford Cancer Institute, Palo Alto, USA.
¹⁶ Seagen Inc., Bothell, USA.

No abstract available

Erratum for

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Curigliano G, et al. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Ann Oncol. 2022. PMID: 34954044 Clinical Trial.